We here show that enhancing Sirt1 activity in IBD LPMC with a pharmacological compound reduces Smad7 acetylation, thereby promoting ubiquitination-driven proteasomal-mediated degradation of Smad7. This evidence concerns the gene SIRT1 and inflammatory bowel disease.